Smart investments, healthy returns
Capital Cell is the world’s leading alternative investment platform for early-stage biotech and life science companies. Selected by experts, backed by visionaries, we give you the chance to shape the future of health, one investment at a time.
Performance to date
Completed
invested
Value
Selected by experts, backed by visionaries
Invest alongside industry titans at the forefront of biotechnology and life sciences.
Alternative Investments: High impact opportunities
Why invest with Capital Cell?
Selected by specialists
Highly curated and carefully vetted, our alternative investments are where health innovation meets wealth generation. Our network of over 3,500 PhD level scientists, IP lawyers, investment consultants and industry professionals analyses a company’s potential for global scale, growth and impact.
Exponential growth potential
Invest in early-stage biotech and life science companies with the potential to scale globally in an emerging, unsaturated market. Make an exponential impact on human health through highly profitable opportunities.
It generates a profound impact on human health with high profitability opportunities.
Diversify your portfolio with purpose
Invest in the forefront of science. Impact the future of human health. Lead the global health revolution with highly curated alternative investment opportunities.
Biotech investments: equity funding yields global impact
At Capital Cell funds companies at the cutting edge of science, developing diagnostics, treatments and tools that will transform the future of healthcare.
Through our expert network of more than 3,500 industry professionals, every investment opportunity allows you to have a profound impact on the global health of the future. Only 3% of the companies that approach Capital Cell are selected to be funded on our platform, each chosen for its potential to scale globally and the opportunity for exceptional profitability.
Invest alongside the best science, investment, and social impact institutions.
Lead the health revolution.
For investors
Learn how our smart investments offer you healthy returns.
For life sciences and biotechnology companies
Learn how we support companies seeking investment and our criteria for selection.
Our network of experts
3.500+
experts are members of the
BioExpert Network
500+
companies have been reviewed
by our experts
The independent network of experts: BioExpert Network
The cornerstone of our evaluation process is the BioExpert Network (BEN), a community of over 3,500 experts in life sciences, health, biotechnology and medicine. The collective wisdom of these highly qualified professionals ensures that only the best biotech investment opportunities make it to our platform.
Success stories we're proud of
Bionure - now Accure Therapeutics - raised €1,200,000 in 2017 and €1,337,000 in 2019 to develop an innovative multiple sclerosis drug.
Vytrus went public through an IPO, giving investors a success with its innovative production of plant cell cultures.
GoodGut's diagnostic and therapeutic technology for digestive diseases continues development and commercialization after its sale to HIPRA.